Pfizer Inc said that its kinase inhibitor, palbociclib, significantly improved progression-free survival in a Phase 2 study of women with advanced breast cancer. A global Phase 3 trial of the drug is currently enrolling patients. ---Subscribe to MedNous to access this article--- Clinical Research Company News
